Paromomycin Sulfate

硫酸巴龙霉素

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameParomomycin Sulfate
Drug Alias NameGabbromicina氨基苷菌素硫酸盐Paromomycin Intramuscular Injection氨基杀菌素硫酸盐Paromomycin sulfate +[24] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Aminoglycoside antibiotics
Mechanisms of Action30S ribosomal subunit inhibitors
Targets30S ribosomal subunit
Therapy Area/IndicationsHIV InfectionsLeishmaniasis, VisceralLeishmaniasis, Cutaneous +[6] 
Global Approved IndicationsAmebiasisInfections
Approved Indications in ChinaInfections
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoEthiopia +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Tropical Medicine AntwerpPfizer Japan IncAppili Therapeutics Inc +[4] 
Inactive CompaniesBanaras Hindu University Medical Alumni Association Of North AmericaNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsLeishmaniasis, CutaneousAmebiasisInfections
Inactive IndicationsHIV InfectionsLeishmaniasis, VisceralCryptosporidiosis

Other Information

ATC CodeA07AA06
Related LinksWikipediaDrugBankKEGG